The use of sodium-glucose cotransporter 2 inhibitors reduced the risk for multiple neurodegenerative diseases in adults with type 2 diabetes, according to study results published in Neurology.
A retrospective cohort analysis found a significantly reduced risk for vascular dementia, Alzheimer’s disease and Parkinson’s disease associated with the use of the type 2 diabetes treatment.
The findings align with recent research that linked sodium-glucose cotransporter 2 (SGLT2) inhibitor use to a 35% to 52% decrease in risk for several types of dementia compared with dipeptidyl peptidase-4 (DPP-4)